Compare · NAVB vs ORKA
NAVB vs ORKA
Side-by-side comparison of Navidea Biopharmaceuticals Inc. (NAVB) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAVB and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $7.27B.
- ORKA has hit the wire 8 times in the past 4 weeks while NAVB has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for NAVB).
- Company
- Navidea Biopharmaceuticals Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- -
- $7.27B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- AMEX
- NASDAQ
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 11
Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Latest NAVB
- Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
- Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
- Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
- Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
- Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
- SEC Form SC 13D/A filed by Navidea Biopharmaceuticals Inc. (Amendment)
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
- SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.
Latest ORKA
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
- General Counsel Quinlan Paul T sold $706,735 worth of shares (9,000 units at $78.53) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana sold $523,648 worth of shares (7,000 units at $74.81) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $805,889 worth of shares (9,999 units at $80.60) as part of a pre-agreed trading plan (SEC Form 4)